Siba P Raychaudhuri, MD
Rheumatology · Sacramento
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Regents of the Univ of CA · 1,571 clinicians in this group
Hospitals listed: University of California Davis Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Raychaudhuri’s office at (916) 827-7463 to ask if they take your plan before you enroll.
California Medical Board record
Licence A52869 · Current
Licensed to practise in California · since 1994 · expires 2027-12-31 · University of Calcutta Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- University of California Davis Medical CenterSacramento, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UC Davis Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 1.94 (1.18 to 2.71) · 3,010 cases, Jul 2022 – Jun 2024Worse than the national rate — MRSA Bacteremia: 1.564, Oct 2024 – Sep 2025Worse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.7 (5.6 to 8) · 1,134 cases, Jan 2024 – Dec 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.6 (10.9 to 14.5) · 1,134 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 127.46 (95.81 to 159.1) · 281 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.18 (0 to 0.57) · 12,625 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.677, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.713, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,436 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for University of California Davis Medical Center
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 1 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.94 (1.18 to 2.71) · 3,010 cases | Worse | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 1.564 | Worse | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.6 to 8) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (10.9 to 14.5) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 127.46 (95.81 to 159.1) · 281 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.57) · 12,625 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.677 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.713 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,436 cases | Better | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.78 to 1.19) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.2 · 115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 662 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 406 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 4,328 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,828 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.13 to 0.46) · 14,152 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.29 (2.92 to 5.66) · 4,920 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.78 (0.46 to 3.09) · 2,250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (1.06 to 3.09) · 4,696 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.46 (5.18 to 13.75) · 2,102 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.35 (3.74 to 8.96) · 2,191 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.48 (1.19 to 3.77) · 1,169 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.826 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.669 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 131 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 751 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -25.8 · 127 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.1 · 758 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.6 · 477 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.3 · 203 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.4 to 14.9) · 2,643 cases | No different | Jan 2022 – Dec 2024 |
What patients said (2,768 patients answered, 18% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 61% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$6,115
Medicare paid this office $6,115 for 49 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 18 | $2,301 | $110 |
| Return visit (30+ min) | 21 | $1,754 | $76 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 18 | $274 | $13 |
Who their Medicare patients are
49 Original Medicare patients in 2024. Average age 70 · Women 69% · Also on Medicaid 37% · Health risk score 1.81. Sicker patients than 9 in 10 peers; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 71% · Diabetes 31% · Depression 24% · Coronary heart disease 22% · Chronic kidney disease 22%.
The office billed $40,383, Medicare allowed $8,422 and paid $6,115; for 88 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 49 | 88 | 70 | 1.81 | $40,383 | $6,115 |
| 2023 | 37 | 52 | 69 | 1.54 | $24,557 | $3,948 |
| 2022 | 30 | 39 | 66 | 1.68 | $19,902 | $3,408 |
| 2021 | 13 | 24 | 68 | 2.09 | $8,903 | $1,941 |
| 2019 | 18 | 35 | 68 | 2.72 | $11,371 | $2,440 |
| 2018 | 17 | 32 | 68 | 2.19 | $10,366 | $2,078 |
| 2016 | 14 | 27 | 59 | 3.28 | $8,663 | $2,367 |
| 2015 | 14 | 30 | 60 | 3.79 | $8,189 | $2,390 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Return visit (30+ min) | 17 | $1,240 | $65 |
Money from drug and device companies
$19,910 in 2025
| 2025 | 6 | 38 | $14,400 | $19,910 |
| 2024 | 3 | 6 | $1,350 | $1,548 |
| 2023 | 3 | 10 | $11,250 | $12,612 |
| 2022 | 2 | 2 | None | $151 |
| 2021 | 2 | 5 | $6,750 | $6,807 |
| 2020 | 6 | 9 | $20,165 | $20,385 |
| 2019 | 5 | 13 | $11,398 | $13,682 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $10,719 | 11 payments
|
| Sun Pharmaceutical Industries | Ilumya | $5,211 | 8 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $1,963 | 15 payments
|
| E.R. Squibb & Sons L.L.C. | None | $1,900 | 1 payment
|
| Ucb | Cimzia | $93 | 2 payments
|
| Merck Sharp & Dohme | None | $26 | 1 payment
|
See all 38 published payments
| Abbvie | Paid to speak or teach · 2025-12-22 | Skyrizi | $3,500 |
| Abbvie | Meals · 2025-12-18 | Skyrizi | $107 |
| Abbvie | Travel · 2025-12-18 | Skyrizi | $532 |
| Abbvie | Meals · 2025-12-02 | Skyrizi | $34 |
| Abbvie | Travel · 2025-12-02 | Skyrizi | $868 |
| Merck Sharp & Dohme | Education · 2025-10-30 | None | $26 |
| Abbvie | Meals · 2025-10-29 | Skyrizi | $47 |
| Ucb | Meals · 2025-10-26 | Bimzelx | $45 |
| Abbvie | Paid to speak or teach · 2025-09-17 | Skyrizi | $2,500 |
| Abbvie | Meals · 2025-08-28 | Skyrizi | $109 |
| Sun Pharmaceutical Industries | Meals · 2025-08-19 | Ilumya | $8 |
| Sun Pharmaceutical Industries | Travel · 2025-08-08 | Ilumya | $228 |
| Sun Pharmaceutical Industries | Meals · 2025-08-08 | Ilumya | $79 |
| Sun Pharmaceutical Industries | Travel · 2025-08-08 | Ilumya | $41 |
| Sun Pharmaceutical Industries | Travel · 2025-08-08 | Ilumya | $41 |
| Sun Pharmaceutical Industries | Travel · 2025-08-08 | Ilumya | $626 |
| Sun Pharmaceutical Industries | Travel · 2025-08-08 | Ilumya | $187 |
| Sun Pharmaceutical Industries | Consulting · 2025-08-08 | Ilumya | $4,000 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-30 | None | $1,900 |
| Abbvie | Paid to speak or teach · 2025-05-30 | Rinvoq | $2,500 |
| Ucb | Meals · 2025-05-21 | Cimzia | $48 |
| Abbvie | Travel · 2025-05-15 | Rinvoq | $476 |
| Abbvie | Meals · 2025-05-15 | Rinvoq | $45 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-08 | None | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-08 | None | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-08 | None | $50 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-08 | None | $125 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-02-08 | None | $91 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-02-08 | None | $130 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-02-08 | None | $606 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-07 | None | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-07 | None | $50 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-07 | None | $75 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-02-07 | None | $210 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-06 | None | $75 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-06 | None | $125 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-02-06 | None | $141 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-02-06 | None | $210 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,548
| Eli Lilly and | None | $1,350 | 1 payment
|
| Ucb | Bimzelx | $189 | 4 payments
|
| Lilly USA | Taltz | $8 | 1 payment
|
2023: $12,612
| Ucb | Bimzelx | $9,825 | 8 payments
|
| Eli Lilly and | None | $2,700 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $88 | 1 payment
|
2022: $151
| Novartis Pharmaceuticals | Cosentyx | $88 | 1 payment
|
| Amgen | Avsola | $63 | 1 payment
|
2021: $6,807
| AbbVie | None | $4,057 | 4 payments
|
| Janssen Scientific Affairs | Tremfya | $2,750 | 1 payment
|
2020: $20,385
| Eli Lilly and | None | $7,000 | 1 payment
|
| Janssen Scientific Affairs | Tremfya | $6,325 | 1 payment
|
| Ucb Sa | None | $3,840 | 1 payment
|
| AbbVie | Rinvoq | $3,030 | 4 payments
|
| Sanofi-Aventis U.S. | Kevzara | $99 | 1 payment
|
| Genentech USA | Actemra | $91 | 1 payment
|
2019: $13,682
| Novartis Pharmaceuticals | Cosentyx | $7,298 | 4 payments
|
| Janssen Biotech | Tremfya | $6,168 | 6 payments
|
| Sanofi-Aventis U.S. | Kevzara | $94 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $75 | 1 payment
|
| Genzyme | Rheumatoid Arthritis Disease | $47 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · Mechanisms of Action of Il17 F in Psoriatic Arthritis · 2025 | Their institution | $97,474 |
| ABBVIE INC. · Regulatory Role of the Jak-1 Signaling System in Psoriatic Disease Mechanism of Action of Upadacitinib (Abt-494) on Plaque and Pannus Formation · 2024 | Their institution | $74,238 |
| Novartis Pharmaceuticals Corporation · Mechanisms of Action of Il17 F in Psoriatic Arthritis · 2024 | Their institution | $62,585 |
| Eli Lilly and Company · Taltz Psa Observational Study · 2024 | Their institution | $56,310 |
| ABBVIE INC. · Regulatory Role of the Jak-1 Signaling System in Psoriatic Disease: Mechanism of Action of Upadacitinib (Abt-494) on Plaque and Pannus Formation. · 2022 | Their institution | $49,963 |
| PFIZER INC. · Xeljanz · 2019 | Their institution | $41,100 |
| AbbVie, Inc. · Rinvoq · 2019 | Their institution | $28,946 |
| ABBVIE INC. · Regulatory Role of the Jak-1 Signaling System in Psoriatic Disease: Mechanism of Action of Upadacitinib (Abt-494) on Plaque and Pannus Formation. · 2023 | Their institution | $28,550 |
| SUN PHARMACEUTICAL INDUSTRIES INC. · Pet Imaging Study in the Cia Mouse Model for Therapeutic Response of Anti-Il23 Antibody · 2021 | Their institution | $28,278 |
| AbbVie, Inc. · 2019 | Their institution | $27,616 |
| AbbVie Inc. · Rinvoq · 2020 | Their institution | $22,375 |
| Janssen Research & Development, LLC · East Bay Institute for Research & Education Psoriasis Study · 2020 | Their institution | $21,176 |
| ABBVIE INC. · A Study Comparing Upadacitinib (Abt-494) To Placebo and To Adalimumab in Participants With Psoriatic Arthritis Who Have An Inadequate Response To at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (Dmard) · 2024 | Their institution | $20,573 |
| ABBVIE INC. · A Study Comparing Upadacitinib (Abt-494) To Placebo and To Adalimumab in Participants With Psoriatic Arthritis Who Have An Inadequate Response To at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (Dmard) · 2022 | Their institution | $14,731 |
| ABBVIE INC. · A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (Abt-494) To Placebo and To Adalimumab in Subjects With Active Psoriatic Arthritis Who Have A History of Inadequate Response To at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (Dmard) - Select - Psa 1 · 2021 | Their institution | $11,162 |
| Novartis Pharmaceuticals Corporation · Mechanisms of Action of Secukinumab in Psa Rgulatory Role on Fls and Endothelial Cell Biology and Its Relevance To Pannus Formation in Psa · 2019 | Their institution | $8,789 |
| ABBVIE INC. · A Study Comparing Upadacitinib (Abt-494) To Placebo and To Adalimumab in Participants With Psoriatic Arthritis Who Have An Inadequate Response To at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (Dmard) · 2023 | Their institution | $7,548 |
| Eli Lilly and Company · Taltz Psa Observational Study · 2025 | Their institution | $1,000 |
| NOVARTIS PHARMACEUTICALS CORPORATION · Research Related Publications Support · 2019 | This clinician | $287 |
| Amgen Inc. · Etanercept Monotherapy in Psa · 2019 | Their institution | $28 |
Professional record
- NPI
- 1821033275
- Licence
- CA A52869California A52869: Current · expires 2027-12-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 510 Ashton Ave, Palo Alto, CA, 94306
- NPI first listed
- 2006-06-19
- NPI last updated
- 2026-07-13
This is when the NPI record was last certified, not a medical board exam.